<DOC>
	<DOCNO>NCT01563627</DOCNO>
	<brief_summary>Epilepsy affect 0.7 % general population 15-20 % patient develop drug resistance . The temporal lobe epilepsy ( TLE ) common symptomatic focal epilepsy particularly high rate drug ( 20 30 % ) . In type epilepsy , feasible , surgical removal home best therapeutic outcome . Mechanisms epileptogenesis drug resistance still mysterious . Of recent clinical experimental study show dysfunction blood-brain barrier ( BBB ) contribute epileptogenesis drug resistance . It recognize cytokine exacerbate excitability permeability BBB , recently confirm study show treatment inflammation reduce epileptogenesis . Moreover , describe association pathological angiogenesis BBB permeability tissue patient excision drug-resistant TLE . With experimental model , reveal activation VEGF-VEGFR2 seizures lead rapid degradation BBB . The investigator hypothesis identification factor involve BBB permeability may designate potential target drug-resistant partial epilepsy .</brief_summary>
	<brief_title>Serum Profile Inflammatory Factors , Immune Angiogenic Temporal Lobe Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Temporal Lobe</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Patient temporal lobe epilepsy ( TLE ) Patient epilepsy least two year . Arm 1 : Patient drugresistant TLE prove potentially candidate surgery . Arm 2 : Patient TLE seizurefree 12 month Patient scalable general pathology may lead increase inflammatory marker : neoplasia , chronic inflammatory disease etc . ... Patient neurological history epilepsy evolutionary potential likely interfere inflammatory marker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>